Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.
A research letter published in JAMA Psychiatry reports that reduced grip strength may represent a transdiagnostic marker across schizophrenia and depression, including remitted depression.
A research letter published in JAMA Psychiatry reports that reduced grip strength may represent a transdiagnostic marker across schizophrenia and depression, including remitted depression.
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic.
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
In a systematic review, greater severity of negative schizophrenia symptoms was associated with decreased health-related quality of life (HRQoL) and worse functional outcomes.
In a systematic review, greater severity of negative schizophrenia symptoms was associated with decreased health-related quality of life (HRQoL) and worse functional outcomes.
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
A large systematic review and meta-analysis found psychological and psychosocial interventions had minimal impact in individuals with co-occurring schizophrenia and substance use disorder (SUD).
Evenamide add-on therapy improved outcomes in patients with treatment-resistant schizophrenia or inadequate antipsychotic response, according to post-hoc analysis findings.
Evenamide add-on therapy improved outcomes in patients with treatment-resistant schizophrenia or inadequate antipsychotic response, according to post-hoc analysis findings.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
